Our results indicate that the elevated expression of SOX2, as a cancer stem cell marker, is remarkably associated with the inferior disease-specific survival and a worsened progression-free interval of CRC patients, which can be used to determine the prognosis of CRC patients in the pathology department as a routine practice. This evidence concerns the gene SOX2 and colorectal carcinoma.